カテゴリー： LP Information, 世界, 医療/バイオ

免疫薬のグローバル市場予測2023-2029

◆英語タイトル：Global Immune Drugs Market Growth 2023-2029

LP Informationが発行した調査報告書（LP23OT8973）◆商品コード：LP23OT8973
◆発行会社（リサーチ会社）：LP Information
◆発行日：2023年10月
◆ページ数：110
◆レポート形式：英語 / PDF
◆納品方法：Eメール（受注後2-3営業日）
◆調査対象地域：グローバル、日本、アメリカ、ヨーロッパ、アジア、中国など
◆産業分野：医薬品＆ヘルスケア
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,660 ⇒換算￥556,320見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD5,490 ⇒換算￥834,480見積依頼/購入/質問フォーム
Corporate User（閲覧人数制限なし）USD7,320 ⇒換算￥1,112,640見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

LP Informationの最新刊調査レポート「免疫薬のグローバル市場」は、過去の販売実績から2022年の世界の免疫薬の総販売量を検討し、2023年から2029年の予測される免疫薬の販売量を地域別・市場分野別に包括的に分析しています。本調査レポートでは、地域別、市場分野別、サブセクター別の免疫薬の市場規模を掲載し、XXX百万米ドル規模の世界の免疫薬市場の詳細な分析を提供します。本インサイトレポートは、世界の免疫薬業界を包括的に分析し、製品セグメント、企業情報、売上、市場シェア、最新動向、M&A活動に関する主要トレンドを明らかにしています。
また、本レポートでは、加速する世界の免疫薬市場における各社の独自のポジションをより深く理解するために、免疫薬製品ポートフォリオ、能力、市場参入戦略、市場でのポジション、海外展開に焦点を当て、主要なグローバル企業の戦略を分析しています。

世界の免疫薬市場規模は、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに成長すると予測され、2023年から2029年までの年平均成長率は000%と予測されます。免疫薬の米国市場は、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに増加し、2023年から2029年までのCAGRは000％と予測されています。免疫薬の中国市場は、2023年から2029年までの年平均000％成長率で、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに増加すると推定されます。免疫薬のヨーロッパ市場は、2023年から2029年にかけて年平均000％成長率で、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに増加すると推定されています。

免疫薬の世界主要メーカーとしては、Antares Pharma, Inc.、 UCB、 Incyte、 GSK、 Takeda、 3S Bio、 Horizo​​n Therapeutics、 Bristol-Myers Squibb (BMS、 Astellas、 Eli Lilly、 Mitsubishi Tanabe Pharma、 Biogen、 Pfizer、 Sanofi、 Roche、 Novartis、 Johnson & Johnson (J&J)、 Amgen、 Abbviなどを掲載しており、売上の面では、世界の2大企業が2022年にほぼ000％のシェアを占めています。

本レポートでは、製品タイプ、用途、主要メーカー、主要地域、国別の免疫薬市場の包括的な概要、市場シェア、成長機会などの情報を提供しています。

【市場セグメンテーション】

この調査では免疫薬市場をセグメンテーションし、種類別 (免疫増強薬、免疫抑制薬)、用途別 (病院、診療所、手術センター、その他)、および地域別 (アジア太平洋、南北アメリカ、ヨーロッパ、および中東・アフリカ) の市場規模を予測しています。

・種類別区分：免疫増強薬、免疫抑制薬

・用途別区分：病院、診療所、手術センター、その他

・地域別区分
南北アメリカ（米国、カナダ、メキシコ、ブラジル）
アジア太平洋（中国、日本、韓国、東南アジア、インド、オーストラリア）
ヨーロッパ（ドイツ、フランス、イギリス、イタリア、ロシア）
中東・アフリカ（エジプト、南アフリカ、イスラエル、トルコ、GCC諸国）

【本レポートで扱う主な質問】

・世界の免疫薬市場の10年間の市場状況・展望は？
・世界および地域別に見た免疫薬市場成長の要因は何か？
・免疫薬の市場機会はエンドマーケットの規模によってどのように変化するのか？
・免疫薬のタイプ別、用途別の内訳は？
・新型コロナウイルスとロシア・ウクライナ戦争の影響は？

********* 目次 *********

レポートの範囲
・市場の紹介
・分析対象期間
・調査の目的
・調査手法
・調査プロセスおよびデータソース
・経済指標
・通貨

エグゼクティブサマリー
・世界市場の概要：免疫薬の年間販売量2018-2029、地域別現状・将来分析
・免疫薬の種類別セグメント：免疫増強薬、免疫抑制薬
・免疫薬の種類別販売量：2018-2023年の販売量、売上、市場シェア、販売価格
・免疫薬の用途別セグメント：病院、診療所、手術センター、その他
・免疫薬の用途別販売量：2018-2023年の販売量、売上、市場シェア、販売価格

企業別世界の免疫薬市場
・企業別のグローバル免疫薬市場データ：2018-2023年の年間販売量、市場シェア
・企業別の免疫薬の年間売上：2018-2023年の売上、市場シェア
・企業別の免疫薬販売価格
・主要企業の免疫薬生産地域、販売地域、製品タイプ
・市場集中度分析
・新製品および潜在的な参加者
・合併と買収、拡大

免疫薬の地域別レビュー
・地域別の免疫薬市場規模2018-2023：年間販売量、売上
・主要国別の免疫薬市場規模2018-2023：年間販売量、売上
・南北アメリカの免疫薬販売の成長
・アジア太平洋の免疫薬販売の成長
・ヨーロッパの免疫薬販売の成長
・中東・アフリカの免疫薬販売の成長

南北アメリカ市場
・南北アメリカの国別の免疫薬販売量、売上（2018-2023）
・南北アメリカの免疫薬の種類別販売量
・南北アメリカの免疫薬の用途別販売量
・米国市場
・カナダ市場
・メキシコ市場
・ブラジル市場

アジア太平洋市場
・アジア太平洋の国別の免疫薬販売量、売上（2018-2023）
・アジア太平洋の免疫薬の種類別販売量
・アジア太平洋の免疫薬の用途別販売量
・中国市場
・日本市場
・韓国市場
・東南アジア市場
・インド市場
・オーストラリア市場
・台湾市場

ヨーロッパ市場
・ヨーロッパの国別の免疫薬販売量、売上（2018-2023）
・ヨーロッパの免疫薬の種類別販売量
・ヨーロッパの免疫薬の用途別販売量
・ドイツ市場
・フランス市場
・イギリス市場
・イタリア市場
・ロシア市場

中東・アフリカ市場
・中東・アフリカの国別の免疫薬販売量、売上（2018-2023）
・中東・アフリカの免疫薬の種類別販売量
・中東・アフリカの免疫薬の用途別販売量
・エジプト市場
・南アフリカ市場
・イスラエル市場
・トルコ市場
・GCC諸国市場

市場の成長要因、課題、動向
・市場の成長要因および成長機会分析
・市場の課題およびリスク
・市場動向

製造コスト構造分析
・原材料とサプライヤー
・免疫薬の製造コスト構造分析
・免疫薬の製造プロセス分析
・免疫薬の産業チェーン構造

マーケティング、販売業者および顧客
・販売チャンネル：直接販売チャンネル、間接販売チャンネル
・免疫薬の主要なグローバル販売業者
・免疫薬の主要なグローバル顧客

地域別の免疫薬市場予測レビュー
・地域別の免疫薬市場規模予測（2024-2029）
・南北アメリカの国別予測
・アジア太平洋の国別予測
・ヨーロッパの国別予測
・免疫薬の種類別市場規模予測
・免疫薬の用途別市場規模予測

主要企業分析
Antares Pharma, Inc.、 UCB、 Incyte、 GSK、 Takeda、 3S Bio、 Horizo​​n Therapeutics、 Bristol-Myers Squibb (BMS、 Astellas、 Eli Lilly、 Mitsubishi Tanabe Pharma、 Biogen、 Pfizer、 Sanofi、 Roche、 Novartis、 Johnson & Johnson (J&J)、 Amgen、 Abbvi
・企業情報
・免疫薬製品
・免疫薬販売量、売上、価格、粗利益（2018-2023）
・主要ビジネス概要
・最新動向

調査結果および結論

❖ レポートの目次 ❖

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Immune Drugs Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Immune Drugs by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Immune Drugs by Country/Region, 2018, 2022 & 2029
2.2 Immune Drugs Segment by Type
2.2.1 Immune Boosting Drugs
2.2.2 Immunosuppressant Drugs
2.3 Immune Drugs Sales by Type
2.3.1 Global Immune Drugs Sales Market Share by Type (2018-2023)
2.3.2 Global Immune Drugs Revenue and Market Share by Type (2018-2023)
2.3.3 Global Immune Drugs Sale Price by Type (2018-2023)
2.4 Immune Drugs Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Surgery Center
2.4.4 Others
2.5 Immune Drugs Sales by Application
2.5.1 Global Immune Drugs Sale Market Share by Application (2018-2023)
2.5.2 Global Immune Drugs Revenue and Market Share by Application (2018-2023)
2.5.3 Global Immune Drugs Sale Price by Application (2018-2023)
3 Global Immune Drugs by Company
3.1 Global Immune Drugs Breakdown Data by Company
3.1.1 Global Immune Drugs Annual Sales by Company (2018-2023)
3.1.2 Global Immune Drugs Sales Market Share by Company (2018-2023)
3.2 Global Immune Drugs Annual Revenue by Company (2018-2023)
3.2.1 Global Immune Drugs Revenue by Company (2018-2023)
3.2.2 Global Immune Drugs Revenue Market Share by Company (2018-2023)
3.3 Global Immune Drugs Sale Price by Company
3.4 Key Manufacturers Immune Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Immune Drugs Product Location Distribution
3.4.2 Players Immune Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Immune Drugs by Geographic Region
4.1 World Historic Immune Drugs Market Size by Geographic Region (2018-2023)
4.1.1 Global Immune Drugs Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Immune Drugs Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Immune Drugs Market Size by Country/Region (2018-2023)
4.2.1 Global Immune Drugs Annual Sales by Country/Region (2018-2023)
4.2.2 Global Immune Drugs Annual Revenue by Country/Region (2018-2023)
4.3 Americas Immune Drugs Sales Growth
4.4 APAC Immune Drugs Sales Growth
4.5 Europe Immune Drugs Sales Growth
4.6 Middle East & Africa Immune Drugs Sales Growth
5 Americas
5.1 Americas Immune Drugs Sales by Country
5.1.1 Americas Immune Drugs Sales by Country (2018-2023)
5.1.2 Americas Immune Drugs Revenue by Country (2018-2023)
5.2 Americas Immune Drugs Sales by Type
5.3 Americas Immune Drugs Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Immune Drugs Sales by Region
6.1.1 APAC Immune Drugs Sales by Region (2018-2023)
6.1.2 APAC Immune Drugs Revenue by Region (2018-2023)
6.2 APAC Immune Drugs Sales by Type
6.3 APAC Immune Drugs Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Immune Drugs by Country
7.1.1 Europe Immune Drugs Sales by Country (2018-2023)
7.1.2 Europe Immune Drugs Revenue by Country (2018-2023)
7.2 Europe Immune Drugs Sales by Type
7.3 Europe Immune Drugs Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Immune Drugs by Country
8.1.1 Middle East & Africa Immune Drugs Sales by Country (2018-2023)
8.1.2 Middle East & Africa Immune Drugs Revenue by Country (2018-2023)
8.2 Middle East & Africa Immune Drugs Sales by Type
8.3 Middle East & Africa Immune Drugs Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Immune Drugs
10.3 Manufacturing Process Analysis of Immune Drugs
10.4 Industry Chain Structure of Immune Drugs
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Immune Drugs Distributors
11.3 Immune Drugs Customer
12 World Forecast Review for Immune Drugs by Geographic Region
12.1 Global Immune Drugs Market Size Forecast by Region
12.1.1 Global Immune Drugs Forecast by Region (2024-2029)
12.1.2 Global Immune Drugs Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Immune Drugs Forecast by Type
12.7 Global Immune Drugs Forecast by Application
13 Key Players Analysis
13.1 Antares Pharma, Inc.
13.1.1 Antares Pharma, Inc. Company Information
13.1.2 Antares Pharma, Inc. Immune Drugs Product Portfolios and Specifications
13.1.3 Antares Pharma, Inc. Immune Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Antares Pharma, Inc. Main Business Overview
13.1.5 Antares Pharma, Inc. Latest Developments
13.2 UCB
13.2.1 UCB Company Information
13.2.2 UCB Immune Drugs Product Portfolios and Specifications
13.2.3 UCB Immune Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 UCB Main Business Overview
13.2.5 UCB Latest Developments
13.3 Incyte
13.3.1 Incyte Company Information
13.3.2 Incyte Immune Drugs Product Portfolios and Specifications
13.3.3 Incyte Immune Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Incyte Main Business Overview
13.3.5 Incyte Latest Developments
13.4 GSK
13.4.1 GSK Company Information
13.4.2 GSK Immune Drugs Product Portfolios and Specifications
13.4.3 GSK Immune Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 GSK Main Business Overview
13.4.5 GSK Latest Developments
13.5 Takeda
13.5.1 Takeda Company Information
13.5.2 Takeda Immune Drugs Product Portfolios and Specifications
13.5.3 Takeda Immune Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Takeda Main Business Overview
13.5.5 Takeda Latest Developments
13.6 3S Bio
13.6.1 3S Bio Company Information
13.6.2 3S Bio Immune Drugs Product Portfolios and Specifications
13.6.3 3S Bio Immune Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 3S Bio Main Business Overview
13.6.5 3S Bio Latest Developments
13.7 Horizo​​n Therapeutics
13.7.1 Horizo​​n Therapeutics Company Information
13.7.2 Horizo​​n Therapeutics Immune Drugs Product Portfolios and Specifications
13.7.3 Horizo​​n Therapeutics Immune Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Horizo​​n Therapeutics Main Business Overview
13.7.5 Horizo​​n Therapeutics Latest Developments
13.8 Bristol-Myers Squibb (BMS
13.8.1 Bristol-Myers Squibb (BMS Company Information
13.8.2 Bristol-Myers Squibb (BMS Immune Drugs Product Portfolios and Specifications
13.8.3 Bristol-Myers Squibb (BMS Immune Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Bristol-Myers Squibb (BMS Main Business Overview
13.8.5 Bristol-Myers Squibb (BMS Latest Developments
13.9 Astellas
13.9.1 Astellas Company Information
13.9.2 Astellas Immune Drugs Product Portfolios and Specifications
13.9.3 Astellas Immune Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Astellas Main Business Overview
13.9.5 Astellas Latest Developments
13.10 Eli Lilly
13.10.1 Eli Lilly Company Information
13.10.2 Eli Lilly Immune Drugs Product Portfolios and Specifications
13.10.3 Eli Lilly Immune Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Eli Lilly Main Business Overview
13.10.5 Eli Lilly Latest Developments
13.11 Mitsubishi Tanabe Pharma
13.11.1 Mitsubishi Tanabe Pharma Company Information
13.11.2 Mitsubishi Tanabe Pharma Immune Drugs Product Portfolios and Specifications
13.11.3 Mitsubishi Tanabe Pharma Immune Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 Mitsubishi Tanabe Pharma Main Business Overview
13.11.5 Mitsubishi Tanabe Pharma Latest Developments
13.12 Biogen
13.12.1 Biogen Company Information
13.12.2 Biogen Immune Drugs Product Portfolios and Specifications
13.12.3 Biogen Immune Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 Biogen Main Business Overview
13.12.5 Biogen Latest Developments
13.13 Pfizer
13.13.1 Pfizer Company Information
13.13.2 Pfizer Immune Drugs Product Portfolios and Specifications
13.13.3 Pfizer Immune Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.13.4 Pfizer Main Business Overview
13.13.5 Pfizer Latest Developments
13.14 Sanofi
13.14.1 Sanofi Company Information
13.14.2 Sanofi Immune Drugs Product Portfolios and Specifications
13.14.3 Sanofi Immune Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.14.4 Sanofi Main Business Overview
13.14.5 Sanofi Latest Developments
13.15 Roche
13.15.1 Roche Company Information
13.15.2 Roche Immune Drugs Product Portfolios and Specifications
13.15.3 Roche Immune Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.15.4 Roche Main Business Overview
13.15.5 Roche Latest Developments
13.16 Novartis
13.16.1 Novartis Company Information
13.16.2 Novartis Immune Drugs Product Portfolios and Specifications
13.16.3 Novartis Immune Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.16.4 Novartis Main Business Overview
13.16.5 Novartis Latest Developments
13.17 Johnson & Johnson (J&J)
13.17.1 Johnson & Johnson (J&J) Company Information
13.17.2 Johnson & Johnson (J&J) Immune Drugs Product Portfolios and Specifications
13.17.3 Johnson & Johnson (J&J) Immune Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.17.4 Johnson & Johnson (J&J) Main Business Overview
13.17.5 Johnson & Johnson (J&J) Latest Developments
13.18 Amgen
13.18.1 Amgen Company Information
13.18.2 Amgen Immune Drugs Product Portfolios and Specifications
13.18.3 Amgen Immune Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.18.4 Amgen Main Business Overview
13.18.5 Amgen Latest Developments
13.19 Abbvi
13.19.1 Abbvi Company Information
13.19.2 Abbvi Immune Drugs Product Portfolios and Specifications
13.19.3 Abbvi Immune Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.19.4 Abbvi Main Business Overview
13.19.5 Abbvi Latest Developments
14 Research Findings and Conclusion

List of Tables
Table 1. Immune Drugs Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Immune Drugs Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Immune Boosting Drugs
Table 4. Major Players of Immunosuppressant Drugs
Table 5. Global Immune Drugs Sales by Type (2018-2023) & (K Units)
Table 6. Global Immune Drugs Sales Market Share by Type (2018-2023)
Table 7. Global Immune Drugs Revenue by Type (2018-2023) & ($ million)
Table 8. Global Immune Drugs Revenue Market Share by Type (2018-2023)
Table 9. Global Immune Drugs Sale Price by Type (2018-2023) & (US$/Unit)
Table 10. Global Immune Drugs Sales by Application (2018-2023) & (K Units)
Table 11. Global Immune Drugs Sales Market Share by Application (2018-2023)
Table 12. Global Immune Drugs Revenue by Application (2018-2023)
Table 13. Global Immune Drugs Revenue Market Share by Application (2018-2023)
Table 14. Global Immune Drugs Sale Price by Application (2018-2023) & (US$/Unit)
Table 15. Global Immune Drugs Sales by Company (2018-2023) & (K Units)
Table 16. Global Immune Drugs Sales Market Share by Company (2018-2023)
Table 17. Global Immune Drugs Revenue by Company (2018-2023) ($ Millions)
Table 18. Global Immune Drugs Revenue Market Share by Company (2018-2023)
Table 19. Global Immune Drugs Sale Price by Company (2018-2023) & (US$/Unit)
Table 20. Key Manufacturers Immune Drugs Producing Area Distribution and Sales Area
Table 21. Players Immune Drugs Products Offered
Table 22. Immune Drugs Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 23. New Products and Potential Entrants
Table 24. Mergers & Acquisitions, Expansion
Table 25. Global Immune Drugs Sales by Geographic Region (2018-2023) & (K Units)
Table 26. Global Immune Drugs Sales Market Share Geographic Region (2018-2023)
Table 27. Global Immune Drugs Revenue by Geographic Region (2018-2023) & ($ millions)
Table 28. Global Immune Drugs Revenue Market Share by Geographic Region (2018-2023)
Table 29. Global Immune Drugs Sales by Country/Region (2018-2023) & (K Units)
Table 30. Global Immune Drugs Sales Market Share by Country/Region (2018-2023)
Table 31. Global Immune Drugs Revenue by Country/Region (2018-2023) & ($ millions)
Table 32. Global Immune Drugs Revenue Market Share by Country/Region (2018-2023)
Table 33. Americas Immune Drugs Sales by Country (2018-2023) & (K Units)
Table 34. Americas Immune Drugs Sales Market Share by Country (2018-2023)
Table 35. Americas Immune Drugs Revenue by Country (2018-2023) & ($ Millions)
Table 36. Americas Immune Drugs Revenue Market Share by Country (2018-2023)
Table 37. Americas Immune Drugs Sales by Type (2018-2023) & (K Units)
Table 38. Americas Immune Drugs Sales by Application (2018-2023) & (K Units)
Table 39. APAC Immune Drugs Sales by Region (2018-2023) & (K Units)
Table 40. APAC Immune Drugs Sales Market Share by Region (2018-2023)
Table 41. APAC Immune Drugs Revenue by Region (2018-2023) & ($ Millions)
Table 42. APAC Immune Drugs Revenue Market Share by Region (2018-2023)
Table 43. APAC Immune Drugs Sales by Type (2018-2023) & (K Units)
Table 44. APAC Immune Drugs Sales by Application (2018-2023) & (K Units)
Table 45. Europe Immune Drugs Sales by Country (2018-2023) & (K Units)
Table 46. Europe Immune Drugs Sales Market Share by Country (2018-2023)
Table 47. Europe Immune Drugs Revenue by Country (2018-2023) & ($ Millions)
Table 48. Europe Immune Drugs Revenue Market Share by Country (2018-2023)
Table 49. Europe Immune Drugs Sales by Type (2018-2023) & (K Units)
Table 50. Europe Immune Drugs Sales by Application (2018-2023) & (K Units)
Table 51. Middle East & Africa Immune Drugs Sales by Country (2018-2023) & (K Units)
Table 52. Middle East & Africa Immune Drugs Sales Market Share by Country (2018-2023)
Table 53. Middle East & Africa Immune Drugs Revenue by Country (2018-2023) & ($ Millions)
Table 54. Middle East & Africa Immune Drugs Revenue Market Share by Country (2018-2023)
Table 55. Middle East & Africa Immune Drugs Sales by Type (2018-2023) & (K Units)
Table 56. Middle East & Africa Immune Drugs Sales by Application (2018-2023) & (K Units)
Table 57. Key Market Drivers & Growth Opportunities of Immune Drugs
Table 58. Key Market Challenges & Risks of Immune Drugs
Table 59. Key Industry Trends of Immune Drugs
Table 60. Immune Drugs Raw Material
Table 61. Key Suppliers of Raw Materials
Table 62. Immune Drugs Distributors List
Table 63. Immune Drugs Customer List
Table 64. Global Immune Drugs Sales Forecast by Region (2024-2029) & (K Units)
Table 65. Global Immune Drugs Revenue Forecast by Region (2024-2029) & ($ millions)
Table 66. Americas Immune Drugs Sales Forecast by Country (2024-2029) & (K Units)
Table 67. Americas Immune Drugs Revenue Forecast by Country (2024-2029) & ($ millions)
Table 68. APAC Immune Drugs Sales Forecast by Region (2024-2029) & (K Units)
Table 69. APAC Immune Drugs Revenue Forecast by Region (2024-2029) & ($ millions)
Table 70. Europe Immune Drugs Sales Forecast by Country (2024-2029) & (K Units)
Table 71. Europe Immune Drugs Revenue Forecast by Country (2024-2029) & ($ millions)
Table 72. Middle East & Africa Immune Drugs Sales Forecast by Country (2024-2029) & (K Units)
Table 73. Middle East & Africa Immune Drugs Revenue Forecast by Country (2024-2029) & ($ millions)
Table 74. Global Immune Drugs Sales Forecast by Type (2024-2029) & (K Units)
Table 75. Global Immune Drugs Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 76. Global Immune Drugs Sales Forecast by Application (2024-2029) & (K Units)
Table 77. Global Immune Drugs Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 78. Antares Pharma, Inc. Basic Information, Immune Drugs Manufacturing Base, Sales Area and Its Competitors
Table 79. Antares Pharma, Inc. Immune Drugs Product Portfolios and Specifications
Table 80. Antares Pharma, Inc. Immune Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 81. Antares Pharma, Inc. Main Business
Table 82. Antares Pharma, Inc. Latest Developments
Table 83. UCB Basic Information, Immune Drugs Manufacturing Base, Sales Area and Its Competitors
Table 84. UCB Immune Drugs Product Portfolios and Specifications
Table 85. UCB Immune Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 86. UCB Main Business
Table 87. UCB Latest Developments
Table 88. Incyte Basic Information, Immune Drugs Manufacturing Base, Sales Area and Its Competitors
Table 89. Incyte Immune Drugs Product Portfolios and Specifications
Table 90. Incyte Immune Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 91. Incyte Main Business
Table 92. Incyte Latest Developments
Table 93. GSK Basic Information, Immune Drugs Manufacturing Base, Sales Area and Its Competitors
Table 94. GSK Immune Drugs Product Portfolios and Specifications
Table 95. GSK Immune Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 96. GSK Main Business
Table 97. GSK Latest Developments
Table 98. Takeda Basic Information, Immune Drugs Manufacturing Base, Sales Area and Its Competitors
Table 99. Takeda Immune Drugs Product Portfolios and Specifications
Table 100. Takeda Immune Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 101. Takeda Main Business
Table 102. Takeda Latest Developments
Table 103. 3S Bio Basic Information, Immune Drugs Manufacturing Base, Sales Area and Its Competitors
Table 104. 3S Bio Immune Drugs Product Portfolios and Specifications
Table 105. 3S Bio Immune Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 106. 3S Bio Main Business
Table 107. 3S Bio Latest Developments
Table 108. Horizo​​n Therapeutics Basic Information, Immune Drugs Manufacturing Base, Sales Area and Its Competitors
Table 109. Horizo​​n Therapeutics Immune Drugs Product Portfolios and Specifications
Table 110. Horizo​​n Therapeutics Immune Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 111. Horizo​​n Therapeutics Main Business
Table 112. Horizo​​n Therapeutics Latest Developments
Table 113. Bristol-Myers Squibb (BMS Basic Information, Immune Drugs Manufacturing Base, Sales Area and Its Competitors
Table 114. Bristol-Myers Squibb (BMS Immune Drugs Product Portfolios and Specifications
Table 115. Bristol-Myers Squibb (BMS Immune Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 116. Bristol-Myers Squibb (BMS Main Business
Table 117. Bristol-Myers Squibb (BMS Latest Developments
Table 118. Astellas Basic Information, Immune Drugs Manufacturing Base, Sales Area and Its Competitors
Table 119. Astellas Immune Drugs Product Portfolios and Specifications
Table 120. Astellas Immune Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 121. Astellas Main Business
Table 122. Astellas Latest Developments
Table 123. Eli Lilly Basic Information, Immune Drugs Manufacturing Base, Sales Area and Its Competitors
Table 124. Eli Lilly Immune Drugs Product Portfolios and Specifications
Table 125. Eli Lilly Immune Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 126. Eli Lilly Main Business
Table 127. Eli Lilly Latest Developments
Table 128. Mitsubishi Tanabe Pharma Basic Information, Immune Drugs Manufacturing Base, Sales Area and Its Competitors
Table 129. Mitsubishi Tanabe Pharma Immune Drugs Product Portfolios and Specifications
Table 130. Mitsubishi Tanabe Pharma Immune Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 131. Mitsubishi Tanabe Pharma Main Business
Table 132. Mitsubishi Tanabe Pharma Latest Developments
Table 133. Biogen Basic Information, Immune Drugs Manufacturing Base, Sales Area and Its Competitors
Table 134. Biogen Immune Drugs Product Portfolios and Specifications
Table 135. Biogen Immune Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 136. Biogen Main Business
Table 137. Biogen Latest Developments
Table 138. Pfizer Basic Information, Immune Drugs Manufacturing Base, Sales Area and Its Competitors
Table 139. Pfizer Immune Drugs Product Portfolios and Specifications
Table 140. Pfizer Immune Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 141. Pfizer Main Business
Table 142. Pfizer Latest Developments
Table 143. Sanofi Basic Information, Immune Drugs Manufacturing Base, Sales Area and Its Competitors
Table 144. Sanofi Immune Drugs Product Portfolios and Specifications
Table 145. Sanofi Immune Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 146. Sanofi Main Business
Table 147. Sanofi Latest Developments
Table 148. Roche Basic Information, Immune Drugs Manufacturing Base, Sales Area and Its Competitors
Table 149. Roche Immune Drugs Product Portfolios and Specifications
Table 150. Roche Immune Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 151. Roche Main Business
Table 152. Roche Latest Developments
Table 153. Novartis Basic Information, Immune Drugs Manufacturing Base, Sales Area and Its Competitors
Table 154. Novartis Immune Drugs Product Portfolios and Specifications
Table 155. Novartis Immune Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 156. Novartis Main Business
Table 157. Novartis Latest Developments
Table 158. Johnson & Johnson (J&J) Basic Information, Immune Drugs Manufacturing Base, Sales Area and Its Competitors
Table 159. Johnson & Johnson (J&J) Immune Drugs Product Portfolios and Specifications
Table 160. Johnson & Johnson (J&J) Immune Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 161. Johnson & Johnson (J&J) Main Business
Table 162. Johnson & Johnson (J&J) Latest Developments
Table 163. Amgen Basic Information, Immune Drugs Manufacturing Base, Sales Area and Its Competitors
Table 164. Amgen Immune Drugs Product Portfolios and Specifications
Table 165. Amgen Immune Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 166. Amgen Main Business
Table 167. Amgen Latest Developments
Table 168. Abbvi Basic Information, Immune Drugs Manufacturing Base, Sales Area and Its Competitors
Table 169. Abbvi Immune Drugs Product Portfolios and Specifications
Table 170. Abbvi Immune Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 171. Abbvi Main Business
Table 172. Abbvi Latest Developments
List of Figures
Figure 1. Picture of Immune Drugs
Figure 2. Immune Drugs Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Immune Drugs Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global Immune Drugs Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Immune Drugs Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Immune Boosting Drugs
Figure 10. Product Picture of Immunosuppressant Drugs
Figure 11. Global Immune Drugs Sales Market Share by Type in 2022
Figure 12. Global Immune Drugs Revenue Market Share by Type (2018-2023)
Figure 13. Immune Drugs Consumed in Hospital
Figure 14. Global Immune Drugs Market: Hospital (2018-2023) & (K Units)
Figure 15. Immune Drugs Consumed in Clinic
Figure 16. Global Immune Drugs Market: Clinic (2018-2023) & (K Units)
Figure 17. Immune Drugs Consumed in Surgery Center
Figure 18. Global Immune Drugs Market: Surgery Center (2018-2023) & (K Units)
Figure 19. Immune Drugs Consumed in Others
Figure 20. Global Immune Drugs Market: Others (2018-2023) & (K Units)
Figure 21. Global Immune Drugs Sales Market Share by Application (2022)
Figure 22. Global Immune Drugs Revenue Market Share by Application in 2022
Figure 23. Immune Drugs Sales Market by Company in 2022 (K Units)
Figure 24. Global Immune Drugs Sales Market Share by Company in 2022
Figure 25. Immune Drugs Revenue Market by Company in 2022 ($ Million)
Figure 26. Global Immune Drugs Revenue Market Share by Company in 2022
Figure 27. Global Immune Drugs Sales Market Share by Geographic Region (2018-2023)
Figure 28. Global Immune Drugs Revenue Market Share by Geographic Region in 2022
Figure 29. Americas Immune Drugs Sales 2018-2023 (K Units)
Figure 30. Americas Immune Drugs Revenue 2018-2023 ($ Millions)
Figure 31. APAC Immune Drugs Sales 2018-2023 (K Units)
Figure 32. APAC Immune Drugs Revenue 2018-2023 ($ Millions)
Figure 33. Europe Immune Drugs Sales 2018-2023 (K Units)
Figure 34. Europe Immune Drugs Revenue 2018-2023 ($ Millions)
Figure 35. Middle East & Africa Immune Drugs Sales 2018-2023 (K Units)
Figure 36. Middle East & Africa Immune Drugs Revenue 2018-2023 ($ Millions)
Figure 37. Americas Immune Drugs Sales Market Share by Country in 2022
Figure 38. Americas Immune Drugs Revenue Market Share by Country in 2022
Figure 39. Americas Immune Drugs Sales Market Share by Type (2018-2023)
Figure 40. Americas Immune Drugs Sales Market Share by Application (2018-2023)
Figure 41. United States Immune Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 42. Canada Immune Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 43. Mexico Immune Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 44. Brazil Immune Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 45. APAC Immune Drugs Sales Market Share by Region in 2022
Figure 46. APAC Immune Drugs Revenue Market Share by Regions in 2022
Figure 47. APAC Immune Drugs Sales Market Share by Type (2018-2023)
Figure 48. APAC Immune Drugs Sales Market Share by Application (2018-2023)
Figure 49. China Immune Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 50. Japan Immune Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 51. South Korea Immune Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 52. Southeast Asia Immune Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 53. India Immune Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 54. Australia Immune Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 55. China Taiwan Immune Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 56. Europe Immune Drugs Sales Market Share by Country in 2022
Figure 57. Europe Immune Drugs Revenue Market Share by Country in 2022
Figure 58. Europe Immune Drugs Sales Market Share by Type (2018-2023)
Figure 59. Europe Immune Drugs Sales Market Share by Application (2018-2023)
Figure 60. Germany Immune Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 61. France Immune Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 62. UK Immune Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 63. Italy Immune Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 64. Russia Immune Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 65. Middle East & Africa Immune Drugs Sales Market Share by Country in 2022
Figure 66. Middle East & Africa Immune Drugs Revenue Market Share by Country in 2022
Figure 67. Middle East & Africa Immune Drugs Sales Market Share by Type (2018-2023)
Figure 68. Middle East & Africa Immune Drugs Sales Market Share by Application (2018-2023)
Figure 69. Egypt Immune Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 70. South Africa Immune Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 71. Israel Immune Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 72. Turkey Immune Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 73. GCC Country Immune Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 74. Manufacturing Cost Structure Analysis of Immune Drugs in 2022
Figure 75. Manufacturing Process Analysis of Immune Drugs
Figure 76. Industry Chain Structure of Immune Drugs
Figure 77. Channels of Distribution
Figure 78. Global Immune Drugs Sales Market Forecast by Region (2024-2029)
Figure 79. Global Immune Drugs Revenue Market Share Forecast by Region (2024-2029)
Figure 80. Global Immune Drugs Sales Market Share Forecast by Type (2024-2029)
Figure 81. Global Immune Drugs Revenue Market Share Forecast by Type (2024-2029)
Figure 82. Global Immune Drugs Sales Market Share Forecast by Application (2024-2029)
Figure 83. Global Immune Drugs Revenue Market Share Forecast by Application (2024-2029)


❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
★リサーチレポート[ 免疫薬のグローバル市場予測2023-2029(Global Immune Drugs Market Growth 2023-2029)]についてメールでお問い合わせはこちらでお願いします。
◆関連リサーチレポート◆
  • 免疫力向上栄養補助食品のグローバル市場予測2023-2029
  • 免疫細胞培養培地のグローバル市場予測2023-2029
  • 免疫細胞無血清培地のグローバル市場予測2023-2029
  • 磁気感応型免疫分析装置のグローバル市場予測2023-2029
  • 世界の免疫薬市場2023年：企業・地域・タイプ・用途別分析

    • ◆H&Iグローバルリサーチのお客様（例）◆